Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting ( pment for thetreatment of advanced ova...)

Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting

pment for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the potential for TELCYTA to treat one or more types of cancer. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, that none of Telik's product candidates have been determined to be safe or effective in humans or been approved for marketing, clinical trials of Telik's product candidates may take several years to complete and may not be successful, success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and interim results of clinical trials do not necessarily predict final results. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2006. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

NOTE: TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.

CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, +1-650-845-7728, or '"/>

Page: 1 2 3
Related medicine technology :

1. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/24/2013)... An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...

(Date:5/24/2013)... YORK , May 24, 2013 In accordance ... Rules and Rule 14e-1 of the United States Exchange Act, ... its original offer for Elan Corporation (NYSE: ELN). ... Limited ("Royalty Pharma") made an offer for the entire of ... Corporation, plc ("Elan") (the "Original Offer"). On ...

(Date:5/23/2013)... , May 24, 2013 3SBio Inc. ... "Company"), a leading China -based ... marketing biopharmaceutical products, announced today that, at an ... Company,s shareholders voted in favor of the proposal ... and plan of merger dated February 8, 2013, ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 2 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement

... CHENGDU, China, Jan. 7, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin ... ), a pharmaceutical company that specializes in patented ... other pharmaceuticals today announced that the Company,s 2010 ... New York Stock Exchange Conference Room 632 on Monday, ...

... 2011 Athersys, Inc. (Nasdaq: ATHX ) today ... present at Retail Investor Confrences.com. DATE: , January 11, ... will be a live, interactive online event where investors are ... the presentation hall as well as the company,s "virtual trade ...

Cached Medicine Technology:Tianyin Pharmaceutical to Hold 2010 Shareholder Annual Meeting on March 21, 2011 at NYSE 2 Athersys to Present Live at Retail Investor Conferences.com on January 11th 2

Tianyin Pharmaceutical to Hold 2010 Shareholder Annual Meeting on March 21, 2011 at NYSE Athersys to Present Live at Retail Investor Conferences.com on January 11th

(Date:5/25/2013)... BC (PRWEB) May 25, 2013 According ... the most beautiful and powerful women that ever lived. ... felt by some of the most powerful men in ... many beauty remedies to keep her skin glowing and ... made with bees- wax, maringa oil and cyprus grass. ...

(Date:5/25/2013)... May 25, 2013 For college ... finals week. Increasingly, they are turning to prescription ... and study. For more on this, go to ... treatment facility, warns that students who pick up ... at risk for developing a physical and psychological ...

(Date:5/25/2013)... May 25, 2013 HealthCrave Medical ... is unique in that it doesn’t just focus ... on treating what causes the noticeable signs of ... Dr. James D. Weiss, M.D., the center provides ... process while helping patients to live longer, healthier ...

(Date:5/24/2013)... A recent study by research group Harris ... upcoming bathing suit season. Almost 138 million people are fearful ... due to weight issues and a quarter admit they feel ... Labs recommends that those anxious about their size consider the ... of an overall effort to improve diet and exercise habits ...

(Date:5/24/2013)... 24, 2013 Compromise is often cited as ... it comes to sleep and comfort. However, many couples find ... individual. For some, this can cause added stress, lost sleep, ... blog, tackles eight common issues in their latest article on ... He Wants Firm: What to do When You Disagree on ...

Breaking Medicine News(10 mins):Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3 Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2 Health News:Anti-Aging Center Offers Advanced Treatment that Controls the Aging Process from Within 2 Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 2 Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 3 Health News:What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples 2

[0] The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician [0] Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals [0] Anti-Aging Center Offers Advanced Treatment that Controls the Aging Process from Within [0] PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful [0] What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples

... Weight Watchers program and obesity training, state,s,largest Medicaid managed ... Association to provide medical professionals the opportunity to ... in conducting Breathe Well, Live Well program, CHARLESTON, ... among the highest in the country in asthma prevalence,UniCare ...

... and HONOLULU, March 12 Allscripts,the leading ... that physicians use to improve healthcare, today ... that provides,technology and support services to more ... statewide license for the Allscripts Electronic Health,Record ...

... in 30% of middle schoolers studied, blamed on acids ... News) -- Dental erosion -- the loss of the ... the United States, researchers say. , "This study is ... prevalence of dental erosion in this country and, more ...

... March 12 As part of its ongoing ... decision-making,Independence Blue Cross today announced that four area ... Complex and Rare Cancers(SM)., Blue Distinction(R) is ... to make wise health care decisions and to ...

... Campaign Features "Superheroes" Theme, WASHINGTON, March 12 ... Agency for Healthcare Research and Quality,(AHRQ) joined with ... public service campaign designed to encourage,Hispanics to become ... urges,Hispanics to stay healthy for their loved ones ...

... TORONTO, March 12 /PRNewswire-FirstCall/ - Bradmer ... the development and,commercialization of cancer therapies, today ... operational and financial results., Operational Highlights, ... 2007, the Company achieved the,following steps in ...

UniCare of West Virginia Providing Assistance for Asthma Education Training Hawaii's Premier Physician Management Company, TeamPraxis, Selects Allscripts Electronic Health Record for Statewide Deployment Dental Erosion on Rise in U.S.Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care Bradmer announces 2007 fourth quarter and fiscal year operational and financial results

Inquire...

Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....

BD Vacutainer® Fluoride Tubes - Glass...

VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....

Medicine Products:

MONOJECT Grey Stopper VACUETTE Glucose tubes - Non-ridged (pull cap)BD Vacutainer® Fluoride (Glucose) Tubes - Glass VACUETTE Trace Element tubes - Ridged (safety screw cap)